Sign in
SuspendedPhase 1/2

Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia

Key facts

Who runs it
Innovent Biologics (Suzhou) Co. Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Suspended
Phase
Phase 1/2
People taking part
222 people, planned
Started
25 Sept 2020
Ended
31 Dec 2024
Type of study
Interventional, 2 groups
Treatments tested
  • IBI188
  • Azacitidine
  • Decitabine
Record updated
23 October 2023
Why it stopped
Pause for changes in development strategies

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • AML patients diagnosed according to WHO AML diagnostic criteria in 2016 (except M3-type and BCR-ABL positive AML)
  • Relapsed// refractory AML( ≥18 ys) or newly diagnosed elderly AML unfit for intensive chemotherapy( ≥60 ys)
  • Age ≥18 years old, gender not limited
  • ECOG score of 0-2
  • Adequate organ function

Who cannot take part

  • Major surgery and vaccine treatment within 4 weeks
  • Uncontrolled concurrent diseases
  • A history of myeloproliferative diseases (including myelofibrosis, primary thrombocytosis, and true red) Cytosis, chronic myelocytic leukemia) or acute myeloid white blood with BCR-ABL1 translocation Patients
  • Acute promyelocytic leukemia, myeloid sarcoma, acute heterozygous leukemia, CMML(accelerated phase and blast phase)
  • Pregnant or breastfeeding female subjects

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The study is to evaluate safety, tolerability and composite CR of IBI188 plus Demethylating Agents in acute myeloid leukemia

The 2 groups in the trial

  • IBI188+azacitidineTreatment being tested

    1L unfit AML receive IBI188 every week by intravenous(IV) and azacitidine daily in Day 1-7 of each four weeks(Q4W) by subcutaneous(IH)

    Treatment: IBI188 and Azacitidine

  • IBI188+decitabineTreatment being tested

    R/R AML receive IBI188 every week by intravenous(IV) and decitabine daily in Day 1-10 of each four weeks(Q4W) by subcutaneous(IH)

    Treatment: IBI188 and Decitabine

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase Ib Study Evaluating the Safety and Efficacy of IBI188 in Combination With Demethylating Agents in Subjects With Acute Myeloid Leukemia
Record updated
23 October 2023
Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia (NCT04485052) – Frontlight Research